Progress in DNA-based heterologous prime-boost immunization strategies for malaria

Immunological Reviews

Volumn 199, Issue , 2004, Pages 126-143

  Moore, Anne C ^a   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; EPITOPE; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA; SPOROZOITE VACCINE; THROMBOSPONDIN; VACCINIA VACCINE;

AMINO ACID SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; GENE GUN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; KAPLAN MEIER METHOD; MALARIA; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; REVIEW; SPOROZOITE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; UNITED KINGDOM;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; MALARIA; MALARIA VACCINES; PEPTIDES; PLASMIDS; PLASMODIUM; VACCINES, DNA; VACCINIA VIRUS;

EID: 2942549544     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00138.x     Document Type: Review

References (104)

1. Marshall E. Malaria. A renewed assault on an old and deadly foe. Science 2000;290:428-430.
2. Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg 2001;64:85-96.
3. Plebanski M,& Hill AV. The immunology of malaria infection. Curr Opin Immunol 2000;12:437-441.
4. Davis JR, Murphy JR, Baqar S, Clyde DF, Herrington DA, Levine MM. Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP) 3. Trans R Soc Trop Med Hyg 1989;83:748-750.
5. Flanagan KL, et al. Ex vivo-gamma immune response to thrombospondin- related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg 2003;68:421-430.
6. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology 2002;124:247-263.
7. Seguin MC, et al. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med 1994;180:353-358.
8. Weiss WR, et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 1990;171:763-773.
9. Renggli J, et al. CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol Lett 1995;46:199-205.
10. Hill AV, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991;352:595-600.
11. Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr Opin Immunol 1999;11:412-419.
12. Takita-Sonoda Y, Tsuji M, Kamboj K, Nussenzweig RS, Clavijo P, Zavala F. Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein. Exp Parasitol 1996;84:223-230.
13. Tsuji M, Romero P, Nussenzweig RS, Zavala F. CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med 1990;172:1353-1357.
14. Renia L, et al. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J Immunol 1993;150:1471-1478.
15. Weiss WR, Sedegah M, Berzofsky JA, Hoffman SL. The role of CD4+ T cells in immunity to malaria sporozoites. J Immunol 1993;151:2690-2698.
16. Charoenvit Y, et al. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect Immun 1999;67:5604-5614.
17. Doolan DL, Hoffman SL. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol 1999;163:884-892.
18. Miller LH, Good MF, Kaslow DC. Vaccines against the blood stages of falciparum malaria. Adv Exp Med Biol 1998;452:193-205.
19. Good MF, Kaslow DC, Miller LH. Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol 1998;16:57-87.
20. Nussenzweig V, Nussenzweig RS. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 1989;45:283-334.
21. Hoffman SL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002;185:1155-1164.
22. Prieur E, et al. A Plasmodium falciparum candidate vaccine based on a six antigen polyprotein encoded by recombinant poxviruses. Proc Natl Acad Sci USA 2004;101:290-295.
23. Ockenhouse CF, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998;177:1664-1673.
24. Nardin EH, Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993;11:687-727.
25. Atkinson CT, Aikawa M, Aley SB, Hollingdale MR. Expression of Plasmodium berghei circumsporozoite antigen on the surface of exoerythrocytic schizonts and merozoites. Am J Trop Med Hyg 1989;41:9-17.
26. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
27. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
28. Ulmer JB, Deck RR, DeWitt CM, Friedman A, Donnelly JJ, Liu MA. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994;12:1541-1544.
29. Hasan UA, Abai AM, Harper DR, Wren BW, Morrow WJ. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999;229:1-22.
30. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-974.
31. Hartikka J, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996;7:1205-1217.
32. Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 2000;20:487-498.
33. Boyer JD, et al. HIV-1 DNA vaccines and chemokines. Vaccine 1999;17:S53-S64.
34. Kim JJ, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999;19:77-84.
35. Kim JJ, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998;28:1089-1103.
36. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002;76:243-250.
37. Shiver JW, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
38. Hanke T, et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 1999;17:589-596.
39. McConkey SJ, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003;9:729-735.
40. Wang R, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
41. Wang R, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001;98:10817-10822.
42. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994;91:9866-9870.
43. Degano P, Schneider J, Hannan CM, Gilbert SC, Hill AV. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999;18:623-632.
44. Leitner WW, et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol 1997;159:6112-6119.
45. Schneider J, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
46. Anderson RJ, et al. Enhanced CD8+ T-cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunisation regimes using a novel attenuated fowlpox virus. J Immunol 2004;172:3094-3100.
47. Gilbert SC, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002;20:1039-1045.
48. Xiang ZQ, Pasquini S, Ertl HC. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol 1999;162:6716-6723.
49. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 2001;98:11491-11496.
50. Li S, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993;90:5214-5218.
51. Moss B, Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol 1987;5:305-324.
52. Satchidanandam V, Zavala F, Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol Biochem Parasitol 1991;48:89-99.
53. Kaplan C. Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch Virol 1989;106:127-139.
54. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors - NYVAC and ALVAC. Dev Biol Stand 1994;82:65-69.
55. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72:1031-1038.
56. Mockett B, Binns MM, Boursnell ME, Skinner MA. Comparison of the locations of homologous fowlpox and vaccinia virus genes reveals major genome reorganization. J Gen Virol 1992;73:2661-2668.
57. Tartaglia J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
58. Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Berl Munch Tierarztl Wochenschr 1999;112:322-328.
59. Schneider J, et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999;170:29-38.
60. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000;74:7651-7655.
61. Schneider J, et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001;19:4595-4602.
62. Hanke T, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-7532.
63. Robinson HL, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999;5:526-534.
64. Barouch DH, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000;97:4192-4197.
65. Barouch DH, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-339.
66. Pancholi P, et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001;33:448-454.
67. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-609.
68. Rogers WO, et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun 2002;70:4329-4335.
69. MacGregor RR, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178:92-100.
70. Calarota S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320-1325.
71. Kester KE, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001;183:640-647.
72. Stoute JA, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86-91.
73. Stoute JA, et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998;178:1139-1144.
74. Bojang KA, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358:1927-1934.
75. Lalvani A, et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999;180:1656-1664.
76. Gilbert SC, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997;15:1280-1284.
77. Degano P, Sarphie DF, Bangham CR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 1998;16:394-398.
78. Moorthy VS, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003;21:2004-2011.
79. Frey SE, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-1274.
80. Robson KJ, et al. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. Am J Trop Med Hyg 1998;58:81-89.
81. Chulay JD, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986;35:66-68.
82. Ponnudurai T, Meuwissen JH, Leeuwenberg AD, Verhave JP, Lensen AH. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans R Soc Trop Med Hyg 1982;76:242-250.
83. Moorthy VS, et al. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J Infect Dis 2003;188:1239-1244.
84. Moorthy V, et al. Phase I evaluation of three highly immunogenic prime-boost regimens for malaria vaccination in Gambian adults including a 12 month re-boosting vaccination. J Infect Dis 2003;188:1239-1244.
85. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5:340-343.
86. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998;394:482-485.
87. Plebanski M, et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998;28:4345-4355.
88. Top FH, Buescher EL, Bancroft WH, Russell PK. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 1971;124:155-160.
89. Chaloner-Larsson G, et al. Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines. Can J Public Health 1986;77:367-370.
90. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6:1574-1583.
91. Cohen CJ, Xiang ZQ, Gao GP, Ertl HC, Wilson JM, Bergelson JM. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 2002;83:151-155.
92. Farina SF, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001;75:11603-11613.
93. Fitzgerald JC, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003;170:1416-1422.
94. Lanar DE, et al. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun 1996;64:1666-1671.
95. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998;72:10180-10188.
96. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-4505.
97. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-1601.
98. Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-4692.
99. Vazquez Blomquist D, Green P, Laidlaw SM, Skinner MA, Borrow P, Duarte CA. Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide. Viral Immunol 2002;15:337-356.
100. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Trends Microbiol 2000;8:410-418.
101. Kotwal GJ. Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol Today 2000;21:242-248.
102. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998;244:365-396.
103. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000;74:923-933.
104. Harte MT, et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003;197:343-351.